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Background: Cocaine exposure has been reported to alter central μ-opioid receptor (MOR) expression in vivo.
The present study employed an in vitro cellular model to explore possible mechanisms that may be involved in this
action of cocaine.
Methods: To assess the effects of cocaine on MOR levels, two treatment regimens were tested in PC12 cells: single
continuous or multiple intermittent. MOR protein levels were assessed by western blot analysis and quantitative
PCR was used to determine relative MOR mRNA expression levels. To evaluate the role of nitric oxide (NO) and
histone acetylation in cocaine-induced MOR expression, cells were pre-treated with the NO synthase inhibitor
Nω-nitro-L-arginine methylester (L-NAME) or the non-selective histone acetyltransferase inhibitor curcumin.
Results: Both cocaine treatment regimens significantly increased MOR protein levels and protein stability, but only
multiple intermittent treatments increased MOR mRNA levels as well as c-fos mRNA levels and activator protein
1 binding activity. Both regimens increased NO production, and pre-treatment with L-NAME prevented
cocaine-induced increases in MOR protein and mRNA levels. Single and multiple cocaine treatment regimens
inhibited histone deacetylase activity, and pre-treatment with curcumin prevented cocaine-induced up-regulation
of MOR protein expression.
Conclusions: In the PC12 cell model, both NO and histone deacetylase activity regulate cocaine-induced MOR
expression at both the transcriptional and post-transcriptional levels. Based on these novel findings, it is
hypothesized that epigenetic mechanisms are implicated in cocaine’s action on MOR expression in neurons.
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Endogenous opioid systems are involved in several aspects
of cocaine addiction [1-5], and several studies have indi-
cated that cocaine increases μ-opioid receptor (MOR)
mRNA and peptide expression [6-11] in regions of the
brain known to regulate incentive motivation and stress
reactivity [12-14]. In rats, cocaine-induced increases in
MOR mRNA expression have been consistently observed
in the ventral striatum [15,16], a region of the brain crit-
ical to drug motivated behaviors [17,18]. Furthermore,
PET studies in abstinent cocaine users have established* Correspondence: bkalisch@uoguelph.ca
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distribution, and reproduction in any mediumcorrelations between elevations in MOR binding in meso-
corticolimbic areas and intensity of cocaine cravings
[19-21]. These data suggest the importance of elucidating
the molecular mechanisms through which cocaine alters
MOR levels in the central nervous system.
The experiments reported in this manuscript were
designed to investigate two possible, and related, mechan-
isms. First, cocaine administration elevates concentrations
of nitric oxide (NO) in the rat brain [22,23], and both co-
caine and NO increase levels, and binding activity, of
members of the activator protein 1 (AP-1) transcription
factor family [24-32]. Because the promoter region of the
MOR gene contains consensus sequences for AP-1 tran-
scription factors [33], it is possible that cocaine modulates
MOR expression via alterations in NO and AP-1 activity.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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lases (HDACs) [34,35], enzymes implicated in the behav-
ioral effects of cocaine in rats [36,37], as well as in
morphine-induced MOR expression [38,39]. HDACs
affect chromatin structure through the removal of acetyl
groups from histones [40-42], and thus contribute to gene
transcription [43-47]. Therefore, it is also likely that co-
caine modulates MOR expression via alterations in his-
tone acetylation.
These experiments employed PC12 cells to investigate
the role of NO and HDACs in cocaine-induced alterations
of MOR expression. This in vitro cellular model was
selected because PC12 cells express the MOR gene
[48-50], their NO pathway has been fairly well charac-
terized [51-54], and they are sensitive to changes in
HDACs activity [55]. Three main results were obtained.
First, cocaine increased MOR protein expression and pro-
tein stability after both single continuous and multiple
intermittent treatment regimens, but only the multiple
intermittent treatment regimen increased expression of
MOR and c-fos mRNAs, as well as AP-1 binding ac-
tivity. Second, NO was identified as an important
modulator, as cocaine increased NO production, and
the NO synthase (NOS) inhibitor Nω-nitro-L-arginine
methylester (L-NAME) attenuated cocaine-induced increases
in MOR protein and mRNA expression. Third, it was found
that cocaine decreased HDACs activity, and inhibition of his-
tone acetyltransferase (HAT) attenuated cocaine-induced




Dulbecco's modified Eagle medium (DMEM), horse
serum, gentamycin, DNAse I, Oligo dT, Superscript II, pri-
mers, Platinum Taq and Lipofectamine 2000 were pur-
chased from Invitrogen (Mississauga, ON, Canada) and
fetal bovine serum (FBS) was obtained from HyClone La-
boratories (Logan, UT, USA). Cocaine HCl was purchased
from Dumex (Toronto, ON, Canada), L-NAME, curcu-
min, and mouse monoclonal anti-α-tubulin were pur-
chased from Sigma Aldrich (St. Louis, MO, USA). The
complete mini tablets were purchased from Roche Diag-
nostics (Laval, QC, Canada), the sodium dodecyl sulfate
(SDS) sample buffer, DTT, and protein standards were
obtained from New England Biolabs (Ipswich, MA) and
the polyclonal MOR antibody was from Abcam
(Cambridge, MA, USA) or Santa Cruz Biotechnology Inc.
(Santa Cruz, CA, USA). Luminol was also purchased from
Santa Cruz. Hybond-C blotting membranes, sheep
anti-mouse IgG and enhanced chemiluminescence (ECL)
kit were obtained from Amersham/GE Health Care
(Piscataway, NJ, USA), poly-D-lysine was from BD Biosciences
(Mississauga, ON, Canada) and 4,5-diaminofluoresceindiacetate (DAF-2 DA) was purchased from Calbiochem
(San Diego, CA, USA). Syber Green PCR master mix was
obtained from Qiagen (Toronto, ON, Canada) and the
HDAC Assay kit was from Active Motif (Carlsbad, CA,
USA). The PathDetect pAP-luciferase reporter plasmid was
obtained from Stratagene (La Jolla CA, USA) and the Luci-
ferase Assay and Galacto-Light (Tropix) kits were from
Promega (Madison, WI, USA) and Applied Biosystems
(Bedford, MA, USA), respectively. All other chemicals
were molecular or electrophoresis grade and obtained
from Fisher Scientific (Ottawa, ON, Canada) or DiaMed
Laboratories (Mississauga, ON, Canada).
Cell culture, viability and treatments
PC12 cells were maintained in DMEM containing 5%
FBS, 5% horse serum and 50 μg/mL gentamycin at 37oC
in 5% CO2. To evaluate the effects of cocaine, NO syn-
thase (NOS) inhibitors, and curcumin on MOR protein
and mRNA levels, cells were plated on CorningW 60 mm
dishes at a density of 1.0 million cells per plate for pro-
tein, and 1.5 million cells per plate for RNA. For the AP-
1 study, PC12 cells were plated on 12-well culture dishes
at a concentration of 2.0 x 105 cells per well. For NO
production imaging, PC12 cells were plated on 6-well
culture dishes containing poly-D-lysine coated coverslips
at a concentration of 2.0 x 105 cells per well. For nuclear
extraction, PC12 cells were plated on 100 mm culture
dishes at a concentration of 4.0 x 106 cells per plate. All
plating was performed 24h prior to any treatment.
The effects of cocaine were determined by exposing
PC12 cells to various concentrations of cocaine using
two different treatments. The doses of cocaine selected
for this study (10, 100, and 500 μM) were based on pre-
vious reports investigating the effects of cocaine on mor-
phological changes and proto-oncogene expression in
PC12 cells [56]. Two treatment regimens were chosen
based on previous findings indicating that different ex-
posure patterns can differentially affect MOR binding af-
finity and receptor density in several regions of the rat
brain [57,58]. These treatments were: single continuous
treatment (SCT) or repeated intermittent treatment
(RIT) (see Table 1). The latter regimen included 3 daily
treatments, each lasting 30 min, separated by 60 min
exposures to cocaine-free media. Cells were harvested
72 h after the beginning of treatment, except where
otherwise indicated.
PC12 cell viability was assessed in control cells and
those exposed to 500 μM SCT or 100 μM RIT with co-
caine for 72 h by the reduction of 3-(4,5-dimethylthiazole-
2-yl)-2,5-diphenyltetrazoliumbromide(MTT)asdescribed
by Cheung et al. [59]. Culture media was replaced with
media containing MTT (0.5mg/mL final concentration)
and the cells were incubated at 37°C for 30 min. The
reduced formazan product was lysed from the cells using
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was subsequently measured at 570nm using the FLUOs-
tar Optima plate-reader (BMG, Fisher Scientific).
The effect of NOS and HAT inhibitors was determined
by pre-treating PC12 cells with inhibitor, for 1 h prior to
cocaine exposure. We determined previously that NGF
increases NOS activity and NO production in PC12 cells
and that this increase is attenuated when cells are pre-
treated with 20 mM L-NAME [53]. Therefore, cells were
pretreated with this dose of L-NAME to examine the in-
volvement of NO in the cocaine-induced expression of
MOR. Cells were also pretreated with 1, 3 or 5 μM of the
non-selective HAT inhibitor curcumin, based on a previ-
ous report by Siddiqui et al. [60], which explored the im-
pact of curcumin on oxidative stress in PC12 cells.
Curcumin was selected for these experiments because it
inhibits HAT in both in vitro and in vivo models [61-63]
and it modulates cocaine place preference in rats [36]. For
RIT, each 30 min cocaine treatment was followed by the
addition of PC12 cell culture media containing only
L-NAME (20 mM) or curcumin (1, 3, 5 μM).
Immunoblot analysis
Control and treated PC12 cells were lysed in 250 μL of
radioimmunoprecipitation assay (RIPA) buffer (final
concentration: 50 mM Tris, 150 mM NaCl, 1% NP-40,
0.25% sodium deoxycholate, 0.5% SDS, 1 mM each of
EDTA, sodium fluoride, sodium orthovanadate and pro-
tease inhibitor (1 Complete Mini Tablet (Roche Diagnos-
tics)/10 mL], pH 7.4). Samples were rocked on ice for 15
min, sonicated, centrifuged at 17 530 g for 15 min and
the protein content of the supernatant determined by
the method of Bradford [64]. Cell lysates (100 μg) were
then boiled in SDS sample buffer (final concentration:
62.5 mM Tris-HCl; pH 6.8, 2% SDS, 42 μM DTT, 10%
glycerol and 0.01% phenol red) and loaded onto a 10%
SDS/polyacrylamide gel.
Following electrophoresis, proteins were transferred
onto nitrocellulose membranes (Hybond-C) using a
Trans-blot semidry transfer unit (Bio-Rad Laboratories,
Mississauga, ON, Canada) with transfer buffer (final
concentration: 28 mM Tris, 39 mM glycine and 20%
methanol, pH 9.2). Membranes were blocked in 2.5% or
5% non-fat milk in tris-buffered saline (TBS) containing
0.1% Tween-20 (TBS-T) for 1 h. Blots were then incu-
bated in 1:750 rabbit MOR antibody in 1% bovine serum
albumin (BSA) in TBS-T for 2 h (Abcam), or in 1:200
rabbit MOR antibody in 1% non-fat milk in TBS-T
(Santa Cruz) overnight. Antibody detection was achieved
using 1:2500 horseradish peroxidase-conjugated donkey
anti-rabbit IgG in either 1 % BSA or 5% non-fat milk in
TBS-T for 1 h, followed by ECL or luminol.
Membranes were scanned using the STORM 860 (Mo-
lecular Dynamics, subsidiary of Amersham) for ECL, orthe Fluorchem 9900 imaging system (Alpha Innotech,
Santa Clara, CA, USA) for luminol. Bands were analyzed
densitometrically using Imagequant (Molecular Dynam-
ics) or Fluorchem 9900 software. Blots were stripped
with 62.5 mM Tris, pH 6.7, containing 2% SDS and 100
mM 2-mercaptoethanol at 50oC for 20 min. Membranes
were then rinsed in TBS for at least 4 h before blocking
with 5 % milk in TBS-T for 1 h and reprobing with 1:50
000 mouse monoclonal anti-α tubulin antibody over-
night. Blots were then exposed to 1:2500 goat anti-mouse
IgG-horse radish peroxidase conjugated secondary anti-
body, in 5% milk in TBS-T and the protein bands visua-
lized as described above.
MOR half-life analysis
Following 72 h of treatment, control and SCT or RIT
PC12 cells were exposed to 10 μg/mL cycloheximide
[65], a de novo protein translation inhibitor, for 4, 8, 12,
24 and 48 h. Cells were then lysed in 250 μL RIPA buf-
fer, and western blot analysis for MOR and α-tubulin
was performed as described above.
Analysis of NO production
NO production was assessed using the fluorescent probe
DAF-2 DA. PC12 cells were treated with cocaine (100 or
500 μM) in the presence or absence of 20 mM L-NAME
for 3 days, washed once with media and loaded with 10
μM DAF-2 DA in 1 mL culture media. Following 2 h of
incubation cells were washed 4 times with 2 mL media
and DAF-2 fluorescence was visualized using an Olym-
pus IX-81 fluorescence microscope (excitation at 488
nm, emission at 520 nm) with an Olympus LucPlan FL
0.40 aperture lens (at 20 x magnification) in phosphate
buffered saline at room temperature. Digital images were
captured using a Cascade 512F camera (Photometrics,
Tucson, AZ, USA), and processed in Q-Capture and
Adobe Photoshop 5.0.
qPCR and PCR analysis
In our previous studies of gene expression in PC12 cells,
changes in mRNA typically occurred 24 to 36 h prior to
changes in protein expression [53]. Therefore we initially
examined MOR mRNA following 48h of SCT and RIT
with cocaine. Control and treated PC12 cells were lysed in
1 mL of Trizol reagent to obtain total RNA. The extracted
RNA was treated with DNase I and reverse transcribed
using superscript II with oligo-dT as the primer for 75
min at 43°C [53]. The resulting cDNA was then used for
real time PCR (qPCR) using a LightCycler (Roche). qPCR
was performed using 1 μL cDNA and 9 μL of QuantiTect
SYBR Green PCR master mix. There was a 15 min incu-
bation period at 95°C prior to the first cycle, and a melting
curve was obtained for each sample following the final
cycle [65]. Primer pairs and cycling conditions were: β-2-
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5’ primer: 5’-TGACCGTGATCTTTCTGGTG-3’ and 3’
primer: 5’-ATCTGAGGTGGGTGGAACTG-3’, 45 cycles
of 95°C: 15 s, 55°C: 25 s, 72°C: 15 s; MOR coding region
(Genbank Accession Number U02083.1): 5’ primer: 5’-
CTGTGTGTTACGGCCTGATG-3’ and 3’ primer: 5’-
ATGCAGAAGTGCCAGGAAAC-3’, 55 cycles of 95°C:
15 s, 52°C: 25 s, 72°C: 15 s. After each cycle, fluorescent
activity was determined, and a final crossing point (thresh-
old cycle, CT) was calculated. Steady-state MOR mRNA
levels relative to β-2 microglobulin were determined with
RelQuant software
To qualitatively observe the effect of cocaine on c-fos
levels, total RNA was extracted from control and trea-
ted PC12 cells as described above 0.5, 1 or 2 h after the
final 30 min 100 μM cocaine treatment on the first day
of RIT. Following reverse transcription, 5 μL cDNA was
combined with 45 μL of master mix containing (final
concentration): 15 mM MgCl2, 10 mM dNTPs, 5 μM of
forward and reverse primers, 10 x PCR buffer, 0.2 μL of
Platinum Taq and water [53,65]. Each PCR was per-
formed with an initial 2 min, 95°C strand separation
and a final 2 min, 72°C elongation. Primer pairs and
cycling conditions were: β-actin (Genbank Accession
number NM_031144): 5’ primer 5’-TCATGAAGTGT-
GACGGTTGACATCCGT-3’ and 3’ primer 5’-CCTA-
GAAGATTTGCGGTGCACGATG-3’, 30 cycles of 95°C:
30 s, 55°C: 30 s, 72°C: 45 s; c-fos coding region (Gen-
bank Accession number NM_022197 XM_234422): 5’
primer: 5’-ACGCGGACTACGAGGCGTCA-3’ and 3’
primer: 5’-GCTCTGGTCTGCGATGGGGC-3’, 40 cycles
of 95°C: 30 s, 55°C: 30 s, 72°C: 45 s. PCR products were
separated on a 1.5% agarose gel stained with ethidium
bromide. Fragments were visualized using the Pharma-
cia Biotech ImageMaster VDS, and images captured
were processed in Microsoft Office Picture Manager. To
quantify steady-state mRNA levels qPCR was performed
as described above and analysis of c-fos levels relative to
β-2 microglobulin determined using RelQuant software.
AP-1 luciferase activity
PC12 cells were fed with antibiotic free media 30 min
prior to transfection. For each well 1.0 μg luciferase re-
porter plasmid containing 7 AP-1 transcription factor
binding elements was incubated with 0.5 μg of a pSV- β-
galactosidase (β-gal) plasmid and 2 μL Lipofecta-
mine2000 in 100 μL OptiMEM for 30 min at room
temperature [51]. The mixture was added to PC12 cells
and the plates returned to the cell culture incubator for
5 h. The transfection medium was replaced with regular
PC12 culture medium and the cells returned to the incu-
bator overnight. Following 6 h of SCT or RIT with co-
caine or 50 ng/mL NGF (used as a positive control for
AP-1 activation [51]) treatment, PC12 cells were lysedwith 200 μL 1X passive lysis buffer (Promega). Lysates
were incubated for 30 min at 4°C, followed by centrifu-
gation at 12 000 x g for 2 min. Duplicate 20 μL samples
of the supernatant were then transferred to a 96 well
plate. To measure luciferase activity, 50μL of Luciferase
Assay Reagent was added to each well, and after a 2 s
delay, luciferase activity was read for 10 s. Luciferase ac-
tivity was an indicator for AP-1 plasmid activation. Du-
plicate samples from the same lysate were used to
measure β-gal activity with the Galacto-Light kit. First,
25 μL of galacton (1:100 with reaction buffer diluent)
was added to each well and the samples were incubated
for 30 to 60 min. This was then followed by the addition
of 50μL of accelerator (provided in the Galacto-Light
kit) to each well, and after a 2 s delay, β-gal activity was
read for 1 s. Luciferase and β-gal activity was measured
using the FLUOstar Optima plate-reader luminometer
(BMG, Fisher Scientific).
Nuclear extraction and HDAC enzyme activity assay
Since c-fos expression and AP-1 activity were altered
within 24 h of treatment, it was hypothesized that co-
caine would alter HDAC activity within a similar time
frame. Following 24 and 36h of SCT and RIT with co-
caine, PC12 cells were harvested in nuclear extraction
buffer A (final concentration: 10 mM HEPES; pH 7.9,
1.5 mM MgCl2, 10 mM KCl, 0.5 μM DTT and protease
inhibitor (1 complete MINI tablet/10 mL)) containing
phosphatase inhibitors (1mM each of sodium fluoride,
sodium orthovanadate). Cells were lysed using a 27.5
gauge needle, and the nuclei were pelleted by centrifuga-
tion at 14 000 x g for 5 min at 4°C. The supernatant was
discarded and the pellet was rinsed in buffer A. Cells
were again centrifuged at 14 000 x g for 5 min at 4°C,
the supernatant discarded and the pellet re-suspended in
nuclear extraction buffer B (final concentration: 20 mM
HEPES; pH 7.9, 1.5 mM MgCl2, 420 mM KCl, 0.5 μM
DTT, 25% glycerol, 2 mM EDTA, 1mM each of sodium
fluoride, sodium orthovanadate, and protease inhibitor
(1 complete MINI tablet/10 mL)) and kept on ice for 15
min. Following the addition of nuclear extraction buffer
C (final concentration: 20 mM HEPES; pH 7.9, 0.5 μM
DTT, 25% glycerol, 0.2 mM EDTA, 1mM each of so-
dium fluoride, sodium orthovanadate, and protease in-
hibitor (1 complete MINI tablet/10 mL)), samples were
centrifuged at 10 000 x g for 5 min. The nuclear fraction
in the supernatant was quantified using the method of
Bradford [64].
Samples were used to detect HDAC enzyme activity
using an HDAC assay kit according to the manufac-
turer’s recommendations. Briefly, nuclear extracts (7 μg)
were added to a 96-well half-volume black plate, mixed
with HDAC assay buffer and HDAC substrate (final con-
centration: 100 μM), and incubated at 37°C for 50 min.
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HDAC developer (containing 2 μM Trichostatin A, final
concentration: 1 μM) and incubated at room temperature
for 12 to15 min. Fluorescence was detected using the
FLUOstar Optima plate reader with an excitation
wavelength at 350 nm and an emission wavelength at
460 nm.
Data Analysis & Statistics
For western blot analysis, each band was analyzed densi-
tometrically as described previously [52,65]. To account
for variability between blots, the densitometric value for
each individual MOR band was expressed as a fraction
of the total amount of MOR protein present on the en-
tire blot (ie. sample MOR density/sum of density of all
MOR bands on blot). The same analysis was carried out
for α-tubulin and then MOR protein values were nor-
malized to α-tubulin values from the same sample.
For qPCR analysis, relative mRNA levels were deter-
mined using the delta-deltaCt method of analysis. A
threshold cycle (CT) was determined for each data point.
A ratio was then determined for each sample using by
the following formula:
Ratio ¼ 2 CT GENEð ÞCT β2Mð Þ½  ð1Þ
where CT(GENE) was the gene of interest, and CT(β2M)
was the CT for β-2-microglobulin. Each data point was
then expressed relative to the control sample.
In order to determine HDAC enzyme activity, a stand-
ard curve was prepared using known HDAC assay
standard dilutions. The amount of fluorescence recorded
was then extrapolated to the pM amount of product
formed (PF) from the standard curve. The specific activ-
ity (SpA) in pM/min/mg was then determined using the
PF, incubation time in min (IT), and mass of nuclear ex-
tract in mg (mnx), by using the following formula:
SpA ¼ PF=ITð Þ=mnx ð2Þ
To determine relative luciferase activity, each sample
was expressed as a percentage of the total amount of
luciferase activity detected for each sample set. Lucifer-
ase activity was then normalized to β-gal activity within
the same sample.
Data are representative of 5 independent experiments
(except where otherwise indicated) and are presented as
the mean ± standard error of the mean (SEM). Data
were assessed for normality and homogeneity of variance
and statistical analysis was carried out using a one or
two-way analysis of variance (ANOVA). In the case of a
one-way ANOVA, analysis was followed by Dunnett’s
test or the Tukey-Kramer Multiple Comparisons test to
determine which groups were significantly different.
One-way ANOVA analysis was carried out for proteinand RNA analysis of MOR levels following cocaine treat-
ment, or for experiments with L-NAME pretreatment.
For RNA analysis with cocaine and L-NAME, the data
did not pass the Bartlett test for homogeneity of vari-
ance, therefore a Kruskal-Wallis non-parametric ANOVA
was performed. For two-way ANOVA with interaction,
analysis was followed by Bonferroni’s multiple compari-
sons t-test to determine which groups were significantly
different. This analysis was used to determine significant
changes in MOR protein expression following cocaine and
curcumin treatments, and used to determine significant
changes in c-fos mRNA expression following cocaine treat-
ments over time. For two-way ANOVA without inter-
action, analysis was followed by contrast analysis to
determine which groups were significantly different, and
was used to determine significant changes in histone dea-
cetylase activity following cocaine administration. Mean
values were considered different if p<0.05.
For the protein half-life and AP-1 experiments, follow-
ing western blot and luciferase analysis as described
above, data were assessed for normality and homogen-
eity of variance. Due to a large disparity between var-
iances, the natural log was taken for each data point. For
the AP-1 luciferase analysis experiment, statistical ana-
lysis was carried out using a one-way ANOVA. Follow-
ing transformation in the protein half-life experiment,
data were analyzed using an analysis of co-variance
(ANCOVA) to determine the effect of each treatment, as
well as significant differences that may exist between the
slopes of the resulting regression lines. The original raw
data was also used to perform an ANCOVA, and, where
possible, the resulting regression line was used to deter-
mine an approximate MOR half-life for each treatment.
Mean values were considered different if p<0.05.
Data analysis was carried out using GraphPad InStat for
one way ANOVA analysis, GraphPad Prism 4.0 or SAS 9.2
(SAS Institute, Cary, NC) for two-way ANOVA analysis
with interaction, and SAS 9.2 for two-way ANOVA ana-
lysis without interaction, as well as ANCOVA analysis.
Results
Cocaine modulates MOR protein and mRNA levels, and
protein half-life
The effect of cocaine on MOR protein levels was evalu-
ated in extracts of control and treated (see Table 1 for
treatment details) PC12 cells using western blot analysis.
Figure 1A displays a representative immunoblot of MOR
levels (upper panel) and corresponding α-tubulin levels
(lower panel) obtained from cells treated with SCT or
RIT with 10, 100 or 500 μM cocaine for 72 h. Densito-
metric analysis (Figure 1B) revealed a significant increase
in MOR protein levels [F(6,33)= 5.75] relative to control
in cells exposed to 500 μM SCT (p<0.05) or 100 μM RIT
Table 1 Cocaine treatment regimens
Regimen Description
SCT A single dose of cocaine added to the cell culture media
and not removed over the entire time-course
RIT Three daily intermittent 30 min treatments applied to the
cells separated by 1 h of regular cell culture media.
PC12 cells were either given a single continuous treatment (SCT) or a repeated
intermittent treatment (RIT) of cocaine.
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PC12 cell viability: metabolic activity assessed with the
MTT reduction assay indicated that, relative to control,
there was only a modest decrease in activity in cocaine-
treated cells (100 μM RIT: 90.1 ± 4.2 % of control, n=4;
500 μM SCT: 93.4 ± 2.9 % of control, n=4), which was
not statistically significant. On the basis of these data,Figure 1 Effect of cocaine on MOR protein and mRNA expression in PC1
control (untreated) and continuous (SCT) or intermittent (RIT) 10, 100, 500 μ
to nitrocellulose membranes. The top panel represents total MOR expressio
(B) Densitometric analysis of MOR protein levels relative to α-tubulin levels
expression following 500 μM SCT or 100 μM RIT compared to control. (C) C
RIT with cocaine for 72 h, followed by 10 μg/mL cycloheximide for 4, 8, 12
normalized to α-tubulin revealed an approximate half-life of 36.3 h in contr
decay following both cocaine treatment regimens. Protein half-life could n
85.3 h was calculated for SCT. (D) Quantitative PCR (qPCR) analysis of MOR
treated cells. Relative to control, 100 μM of RIT with cocaine significantly in
are representative of at least 5 independent experiments and the data are
**^p=0.001).500 μM SCT and 100 μM RIT cocaine were used in sub-
sequent experiments.
To determine whether the cocaine-induced increase in
MOR protein level was due to an increase in protein sta-
bility, protein extracts were obtained from cells treated
for 72 h with 500 μM SCT or 100 μM RIT cocaine fol-
lowed by 10 μg/mL cycloheximide for 4, 8, 12, 24 or 48 h.
Densitometric analysis of MOR protein levels relative to
α-tubulin revealed an estimated MOR half-life of 36.3 h in
control (untreated) cells (Figure 1C), and a statistically
significant effect of cocaine [F(2, 103)= 13.94, p<0.0001]
and time (h) [F(1, 103) = 17.11, p<0.0001]. Both treat-
ment regimens significantly changed the slope of protein
decay compared to control, indicating that cocaine
increased MOR half-life. Although it was not pos-
sible to calculate a predicted half-life for the cells treated2 cells. (A) Representative immunoblots obtained from lysates of
M cocaine treated PC12 cells separated by SDS-PAGE and transferred
n and the bottom panel shows α-tubulin levels from the same blot.
in cocaine-treated cells revealed a significant increase in MOR
ell lysates were obtained from cells exposed to 500 μM SCT or 100 μM
, 24 and 48 h. Densitometric analysis of MOR protein expression
ol (untreated) cells, and a significant change in the slope of protein
ot be estimated for RIT, but an increase in the predicted half-life to
mRNA levels relative to β-2 microglobulin in control and cocaine
creased MOR mRNA levels while 500 μM of SCT had no effect. Results
presented as mean ± SEM (*p<0.05, **p<0.01, ***p< 0.001,
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exposure to 500 μM SCT was estimated to be 85.3 h.
The effect of cocaine on MOR mRNA levels was also
examined (Figure 1D). RNAwas isolated from cells treated
for 48 h with either 500 μM SCT or 100 μM RIT cocaine
and levels of MOR mRNA relative to β2-microglobulin
were assessed by reverse transcriptase (RT)-real time PCR
(qPCR) analysis. Compared to control, a statistically sig-
nificant increase in relative MOR mRNA levels was
detected in cocaine-treated cells following RIT [F(2,15)=
6.80, p<0.01], but not SCT.
Effect of cocaine on nitric oxide, and its role in MOR
protein and mRNA expression
To examine the effect of cocaine on NO production,
PC12 cells were treated with 500 μM SCT or 100 μM RIT
for 72 h and diaminofluorescein-2 (DAF-2) fluorescence
was examined. A low level of DAF-2 fluorescence, indica-
tive of NO production, was observed in untreated PC12
cells (Figure 2A). DAF-2 fluorescence was increased in
cocaine-treated cells with both treatments, and this in-
crease was prevented when cells were pretreated with the
non-selective NOS inhibitor L-NAME (20 mM).
In the subsequent experiment, PC12 cells were treated
with 20 mM of L-NAME prior to 500 μM SCT or 100 μM
RIT cocaine. Representative western blots depicting MOR
and α-tubulin levels in extracts obtained from cells treated
with cocaine in the presence or absence of L-NAME are
presented in Figure 2B, and densitometric analysis of
MOR expression relative to α-tubulin is depicted in
Figure 2C. Relative to control, a significant increase in
MOR protein levels was observed in cells treated for 72 h
with either 500 μM SCT or 100 μM RIT cocaine [F(5,26)=
3.43, p<0.05 for both treatments]. This increase was not
observed in cells pretreated with L-NAME.
The final experiment assessed the effect of 20 mM
L-NAME pretreatment on MOR mRNA levels increased
following 100 μM RIT cocaine. Compared to control,
qPCR analysis (Figure 2D) revealed that cocaine signifi-
cantly increased relative MOR mRNA levels (Kruskal-
Wallis statistic= 15.36, p<0.001), and that this was
prevented by pretreatment with L-NAME.
Effect of cocaine on c-fos mRNA levels and AP-1 binding
Qualitative assessment of c-fos levels in PC12 cells treated
with 100 μM RIT cocaine for 0.5, 1 or 2 h, revealed
increases in steady-state c-fos mRNA (Figure 3A) relative
to control. This was confirmed by qPCR analysis
(Figure 3B) which revealed cocaine significantly increased
relative c-fos mRNA levels [F(1,21)=11.41, p<0.01]. No in-
crease in c-fos was detected following SCT cocaine. To in-
vestigate the effect of cocaine on AP-1 activity, PC12 cells
were transiently transfected with a plasmid containing 7
AP-1 binding elements upstream from a luciferasereporter gene. The day after transfection, cells were
exposed to 10, 100 or 500 μM SCT or RIT cocaine and
harvested 6 h after the start of treatment (Figure 3C). As a
positive control, other cells were treated with 50 ng/mL
nerve growth factor (NGF) for 6 h [51]. Although modest
compared to the NGF-mediated increase in AP-1 activity,
both 10 and 100 μM RIT cocaine significantly increased
AP-1 activity compared to control [F(7,33)= 10.181,
p<0.01 for NGF, p<0.05 for cocaine]. No increase in luci-
ferase activity was detected following SCT at all of the
doses tested.
Effect of cocaine on HDACs, and the role of histone
acetylation in MOR protein expression
PC12 cells were treated with 500 μM SCT or 100 μM
RIT cocaine, and HDACs activity in nuclear extracts was
evaluated 24 or 36 h after treatment (Figure 4A). Follow-
ing both time points and treatments, HDACs activity
was significantly inhibited in comparison to control
[F(2, 29)= 3.43, p<0.05]. There was no difference in
the level of HDAC inhibition between either treat-
ment conditions or treatment times.
In a subsequent experiment, PC12 cells were treated
with 1, 3 or 5 μM curcumin, a non-selective HAT inhibi-
tor, for 1h prior to exposure to either 500 μM SCT or
100 μM RIT cocaine for 72h. Relative levels of MOR
protein from these cell extracts was compared to those
obtained from untreated cells, and those treated with
the inhibitor or cocaine alone. Statistical analysis
revealed an overall significant interaction between the
effects of curcumin and cocaine on MOR protein ex-
pression [F(6, 52)= 15.25, p<0.0001], a significant effect
of curcumin alone [F(3, 52)= 20.62, p<0.0001], and a sig-
nificant effect of cocaine alone [F(2, 52)= 15.87,
p<0.0001]. Pre-treatment with 3 μM curcumin signifi-
cantly decreased MOR expression in cells treated with
500 μM SCT cocaine compared to cocaine alone
(p<0.0001). Additionally, MOR levels in cells pre-treated
with 1, 3, and 5 μM curcumin followed by 100 μM RIT
cocaine were significantly lower than those receiving
RIT cocaine alone (p<0.05 for 1 μM, p<0.0001 for 3 and
5 μM curcumin).
Discussion
The present study identified a number of cellular mechan-
isms by which cocaine alters MOR expression. Treatment
of PC12 cells with either a single dose or repeated doses
of cocaine increased MOR protein levels. The mechan-
isms regulating this increase were dependent on the treat-
ment regimen used. Both SCT and RIT increased MOR
protein stability, indicating that both regimens increased
MOR protein levels post-transcriptionally. RIT elevated
MOR and c-fos mRNA levels and AP-1 activity, but a sin-
gle dose of cocaine did not, indicating that multiple
Figure 2 Effect of cocaine on NO levels, and NOS inhibition on MOR protein and mRNA levels. (A) Representative images depicting DAF-2
fluorescence in (i) control (untreated) cells and cells treated with (ii) 500 μM SCT, or (iii) 100 μM RIT with cocaine for 72 h. The left column depicts
fluorescence, the middle column is the corresponding Nomarski differential interference contrast image, and the right column is the overlay of
these two images. Basal fluorescence was detected in control treated PC12 cells. Following exposure of cells to 500 μM SCT and 100 μM RIT,
fluorescence intensity increased. The cocaine-induced increase in DAF-2 fluorescence was prevented when cells were pretreated with 20 mM
L-NAME in both treatment regimens (iv and v). (B) Representative immunoblot of MOR protein (upper panel) and α-tubulin (lower panel) levels
obtained from lysates of control (untreated) and cocaine-treated PC12 cells grown in the presence or absence of 20 mM L-NAME. Cells were
exposed to 500 μM SCT or 100 μM RIT with cocaine for 72 h. (C) Densitometric analysis of MOR protein expression relative to α-tubulin in control,
cocaine and L-NAME treated cells. Relative to control, cocaine (SCT and RIT) significantly increased relative MOR protein levels and this increase
was prevented in cells pretreated with L-NAME. (D) qPCR analysis of MOR mRNA expression relative to β-2 microglobulin in control, cocaine (100
μM RIT) and L-NAME (alone or in combination with 100 μM RIT cocaine) treated PC12 cells. Relative to control, 100 μM RIT of cocaine significantly
increased MOR mRNA, and this increase was prevented by pre-treatement with 20 mM L-NAME. Results are representative of at least 5
independent experiments and the data are shown as mean ± SEM (*p<0.05, ***p<0.001).
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of MOR. Both dosing regimens also increased NO
production and inhibited HDACs activity. Finally,
cocaine-induced increases in MOR expression were
attenuated by pretreatment with the NOS inhibitorL-NAME, and by the non-selective HAT inhibitor
curcumin. Therefore, in PC12 cells, both NO and
histone acetylation play an important role in the
transcriptional and post-transcriptional regulation of
MOR levels by cocaine.
Figure 3 Effect of cocaine on c-fos mRNA levels and AP-1 activity. (A) Representative ethidium bromide-stained gel showing amplification of
c-fos (upper band) and β-actin (lower band) transcripts obtained from RNA extracted from control and cocaine-treated (100 μM RIT) PC12 cells,
and harvested 0.5, 1, or 2 h after the last of three intermittent cocaine treatments. Qualitative assessment indicated that compared to control,
cocaine exposure increased levels of c-fos mRNA at all of the time-points examined. (B) Quantitative PCR (qPCR) analysis of c-fos mRNA levels
relative to β-2 microglobulin in control and cocaine treated cells. Relative to control, 100 μM of RIT with cocaine significantly increased c-fos
mRNA levels [F(1,21)=11.41, p<0.01]. (C) PC12 cells were transiently transfected with a luciferase-reporter plasmid containing 7 AP-1 transcription
factor binding sites prior to treatment with 50 ng/mL NGF or cocaine (10, 100, or 500 μM SCT or RIT) for 6 h. Luciferase activity in each sample
was normalized to its corresponding β-gal activity. Relative to control, there was a significant increase in luciferase activity in PC12 cells treated
with NGF, or 10 or 100 μM RIT with cocaine. Results are representative of at least 5 independent experiments and data are presented as the
mean ± SEM (*p<0.05, **p<0.01).
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Figure 4 Effect of cocaine on HDAC activity, and inhibition of HAT on cocaine-induced MOR protein levels. (A) Nuclear extracts were
obtained from lysates of PC12 cells treated with cocaine (500 μM SCT or 100 μM RIT) for 24 or 36 hours. HDAC enzyme activity was determined
using a fluorescent microplate reader and expressed as specific activity, in pM/min/mg. Statistical analysis revealed a significant decrease in HDAC
activity following both cocaine treatment regimens at both 24 and 36 h. (B) Densitometric analysis of MOR protein levels relative to α-tubulin in
control and 72 h cocaine (100 μM SCT and 500 μM RIT) treated cells grown in the presence and absence of 1, 3 or 5 μM curcumin. Compared to
control, both SCT and RIT with cocaine increased MOR protein levels. For SCT, there was a significant decrease in MOR expression after pre-
treatment with 3 μM curcumin compared to cells treated with cocaine alone. Pre-treatment with 1, 3 and 5 μM curcumin also prevented the
increase in relative MOR protein levels resulting from 100 μM RIT. Results are representative of at least 5 independent experiments and data are
presented as mean ± SEM (*p<0.05, ****p<0.0001 compared to control, #p<0.05, ####p<0.0001 compared to cocaine alone).
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levels and receptor density in several regions of the rat
brain [6,7,66]. In the PC12 cellular model, both repeated
doses and a single dose of cocaine increased MORprotein levels, but only repeated doses elevated MOR
mRNA levels. This suggests that different treatment
regimens regulate MOR expression through different
mechanisms, and that multiple doses of cocaine are
Winick-Ng et al. BMC Pharmacology and Toxicology 2012, 13:11 Page 11 of 16
http://www.biomedcentral.com/bmcpharmacoltoxicol/2050-6511/13/1/11necessary for transcriptional regulation of the MOR. To
investigate this possibility further, the effect of RIT and
SCT cocaine on potential transcriptional regulators of
MOR expression, c-fos expression and AP-1 activity, was
also assessed.
Several studies have demonstrated increases in c-Fos
levels following cocaine administration [27,30,31,40,67].
c-Fos binds to members of the Jun immediate early gene
family to form the AP-1 transcription factor [68,69].
Since the promoter of the MOR gene contains consen-
sus sequences for binding AP-1 transcription factors
[33], AP-1 activity was assessed in PC12 cells treated
with cocaine. It was found that the effect of cocaine on
AP-1 activity was dependent on the treatment regimen.
In fact, only exposure to multiple cocaine doses
increased c-fos mRNA levels and AP-1 activity, suggest-
ing that increased MOP-r mRNA levels induced by
100 uM RIT in PC12 cells could be mediated by AP-1.
Increased c-fos expression following repeated in vivo
cocaine administration has been linked to cocaine-
induced phosphorylation of CREB [70]. Since CREB is
an important regulator of c-fos transcription (reviewed
in [71]), it is possible the increased c-fos mRNA levels
observed following RIT in the present study are the re-
sult of cocaine-induced CREB phosphorylation. Al-
though we only focused on one potential candidate,
other transcription factors, such as SP-1 and NF-κB
are also increased in PC12 cells following cocaine ad-
ministration. [72,73] and activation of these transcrip-
tion factors has been linked to increases in MOR
transcription and mRNA expression [74-76]).
The present study also investigated the role of NO in
regulating cocaine-induced changes in MOR protein
levels. NO has been found to contribute to the behavioral
effects of cocaine, including conditioned place preference
and sensitization [77-83]. In addition, NO has been
reported to modulate CREB phosphorylation and DNA
binding [84,85], increase the expression of immediate
early genes such as c-Fos and Jun-B [25,28,29] and in-
crease transcription from AP-1 responsive promoters
[25,29], suggesting that NO could also be involved in
regulating MOR transcription. In PC12 cells, pre-
treatment with the NOS inhibitor L-NAME prevented
cocaine-induced up-regulation of MOR mRNA and pro-
tein. Additionally, NO production was assessed visually by
loading the cells with DAF-2DA as described previously
[53]. Both 100 μM RIT and 500 μM SCT cocaine substan-
tially enhanced DAF-2 fluorescence relative to control
(untreated) cells indicating both dosing regimens result in
increased NO production. This cocaine-mediated increase
in DAF-2 fluorescence was blocked by pre-treated with 20
mM L-NAME, the dose of L-NAME that also prevented
cocaine-induced increases in MOR protein and mRNA
levels. Taken together, these findings indicate that NOmodulates cocaine-induced changes in MOR protein
levels. Interestingly, in in vivo neuronal models, cocaine
increases NO production by increasing neuronal NOS
(nNOS) protein levels and activation [22,23,78,79] via
dopamine-, glutamate- and MOR-dependent mechanisms
[22,23,79]. Because the PC12 cell culture model does not
contain these pre- and post-synaptic systems, the current
findings support the intriguing possibility that cocaine can
alter NO levels and/or activity by direct intracellular
actions. The specific target of these direct actions, and its
biological significance, will require further investigation.
These experiments in PC12 cells identified another
possible mechanism through which cocaine could in-
crease MOR expression. NO has been reported to de-
crease HDACs activity [34,35], enzymes that are linked
to the behavioral effects of cocaine in rats [36,37], and in-
hibition of these enzymes prolongs histone acetylation
and contributes to enhanced transcription [43-47]. In the
present study, both RIT and SCT cocaine decreased
HDACs activity indicating that in vitro cocaine exposure
enhances histone acetylation. In addition, pre-treatment
with the non-selective HAT inhibitor curcumin pre-
vented the cocaine-induced up-regulation of MOR pro-
tein levels for both dosing regimens. In vivo studies in
rats have demonstrated that cocaine increases histone
acetylation [36,86,87]. Our findings complement and ex-
tend these findings, and suggest that cocaine-mediated
alterations in histone acetylation could be an important
regulator of MOR protein levels. However, additional
actions of curcumin could also contribute to these
effects. In fact, cocaine induces the expression of cyto-
kines, such as interleukin-1β [88] which can also regulate
MOR transcription [89]. Curcumin inhibits interleukin-
1β-induced NF-κB activation [90], suggesting the possi-
bility that the anti-inflammatory properties of curcumin
could contribute to its ability to inhibit MOR
transcription.
The relationship between NO and HDACs is also
complex. Although the cocaine-induced increase in NO
observed in the present study could be responsible for
decreasing HDACs activity, inhibition of HDACs has
also been associated with increases in eNOS mRNA
[91]. Increased constitutive NOS levels and increases in
NO production resulting in S-nitrosylation have been
reported to regulate protein stability [43,44,47]. Thus, in
the PC12 cell model, NO and HDACs could modulate
MOR expression independently, or may regulate each
other to affect MOR transcription and protein stability.
As well, the cocaine-induced increase in c-fos expression
and AP-1 activity, only observed after RIT, together with
increased histone acetylation could be involved in the
transcriptional regulation of MOR. Interestingly, both
cocaine and NO were reported to increase c-fos expres-
sion in vivo [92], and increases in c-fos are correlated
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caine administration and H4 histones after a single acute
dose [93], suggesting that similar cellular mechanisms
could be regulating the effects of cocaine in vitro and
in vivo.
Although we identified NO and histone acetylation as
important regulators of cocaine-induced MOR protein
expression, how cocaine initiated the observed effects
remains unclear. Blockade of sodium channels following
passive entry of cocaine into PC12 cells is one possibil-
ity. However, this may not be the only mechanism be-
cause, in PC12 cells, NO activity is associated with
extracellular signal-regulated kinase (ERK) pathway acti-
vation [94-97], and Tan et al. [98] found that the select-
ive sodium channel inhibitor tetrodotoxin had no effect
on this pathway. We determined previously that NO
modulates ERK activity in PC12 cells [54], and since
blockade of ERK phosphorylation in the nucleus accum-
bens of rats inhibits cocaine-induced behavioural
sensitization [99], it is possible that in our system NO-
mediated activation of ERK contributes to cocaine-
induced MOR expression. In vivo cocaine exposure
increases dopamine accumulation, through inhibition of
dopamine reuptake by the dopamine transporter (forFigure 5 Schematic representation of the proposed mechanisms for the
production and decreases HDAC activity, which could lead to further incre
Multiple repeated treatments with cocaine also lead to increases in the lev
to stimulate AP-1 activity, which, in combination with HDAC inhibition, ma
enhanced transcription. Sites of inhibition (⊥) by curcumin and L-NAME arreviews, see: [14,100]), and the dopamine transporter
inhibitor sydnocarb has been shown to increase NO
generation [101]. Interestingly, Imam et al. [56] reported that
cocaine, increased NFκB expression, and dose-dependently
decreased both dopamine transporter expression and
intracellular dopamine concentrations in differen-
tiated PC12 cells. Elevations in extracellular dopa-
mine could result in dopamine receptor activation,
and inhibition of the D1 sub-type of dopamine re-
ceptor was reported to partially inhibit cocaine-induced in-
crease in NF-κB [73]. Because NF-κB has also been
implicated in regulating NOS expression and NO produc-
tion [102,103], indirect activation of the D1 receptor by co-
caine could enhance NO production. Whether the
increases in NO observed in the current study resulted
from cocaine-induced dopamine accumulation and dopa-
mine receptor activation requires further investiga-
tion. Finally, cocaine has also been reported to diffuse
through the membrane of cells [104], suggesting that it
may exert direct effects on gene or protein expression.
There are several advantages to identify cellular
mechanisms in cell lines, however some limitations of
this system need to be considered. In contrast to neu-
rons, PC12 cells continue to divide, and this could makein vitro action of cocaine on MOR expression. Cocaine increases NO
ases in NO production as well as enhanced MOR protein stability.
els of c-fos mRNA. c-Fos can bind to Jun transcription family members
y contribute to an up-regulation in MOR mRNA levels through
e indicated.
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though we have identified many similarities between our
findings and previous in vivo studies, differences in the
biology of cocaine in the intact organisms compared to
the effects observed in vitro are likely to exist. The
physiological relevance of the doses and regimens
employed in these in vitro studies is also not known.
The doses selected for the present study were based on
a previous study that characterized changes in proto-
oncogene expression in differentiated PC12 cells [56]. It
is not known whether similar treatment regimens, or
doses of cocaine, would exert similar effects in an
in vitro neuronal model or in vivo. Further the authors
are not aware of any study that has established concen-
trations of cocaine in the extracellular fluid required to
initiate changes in NO production or epigenetic modifi-
cations in neurons, or whether cocaine can act on these
mechanisms by pathways that do not involve the trans-
porters of catecholamines. Therefore, the current results
in the PC12 cell model are important as they propose
testable hypotheses about cellular and molecular
mechanisms through which cocaine modulates MOR
protein and gene expression in neurons.
Conclusions
The data presented in this study support a model in which
cocaine enhances MOR protein expression by increasing
cellular NO levels and by decreasing HDAC activity
(Figure 5). In addition to cocaine activating these effects
independently, elevations in NO could also alter HDAC
activity. Inhibition of HDACs could further enhance NO
production, resulting in increased MOR expression and
protein stability. Additionally, increases in c-fos (following
multiple treatments) may lead to a modest increase
in AP-1 activity that, in combination with enhanced his-
tone acetylation, could contribute to the up-regulation of
MOR transcription. Whether these mechanisms occur in
neurons, and whether they have implications for the behav-
ioral effects of cocaine, should be the focus of additional
investigations.
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